(0.36%) 5 118.49 points
(0.30%) 38 353 points
(0.38%) 15 988 points
(-1.10%) $82.93
(3.48%) $1.990
(0.01%) $2 347.40
(0.08%) $27.56
(3.18%) $951.45
(-0.04%) $0.934
(-0.06%) $11.02
(-0.30%) $0.798
(1.84%) $93.56
Live Chart Being Loaded With Signals
KYORIN Holdings, Inc., through its subsidiaries, researches and develops, produces, and sells ethical and generic drugs in Japan and internationally. The company offers Flutiform, a drug for the treatment of asthma; Desalex, an antiallergic agent; Beova, Uritos, and Imidafenacin KYORIN therapeutic agents for overactive bladder; Lasvic, a quinolone synthetic antibacterial agent; Pentasa, a remedy for ulcerative colitis/Crohn's disease; Nasonex, an allergic rhinitis therapeutic agent; and Kipres, a leukotriene receptor antagonist anti-bronchial asthma and allergic rhinitis drug...
Stats | |
---|---|
本日の出来高 | 84 900.00 |
平均出来高 | 69 440.00 |
時価総額 | 105.02B |
EPS | ¥0 ( 2024-02-05 ) |
次の収益日 | ( ¥0 ) 2024-05-08 |
Last Dividend | ¥32.00 ( 2023-03-30 ) |
Next Dividend | ¥0 ( N/A ) |
P/E | 24.63 |
ATR14 | ¥1.224 (0.07%) |
ボリューム 相関
KYORIN Holdings, Inc. 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
KYORIN Holdings, Inc. 相関 - 通貨/商品
KYORIN Holdings, Inc. 財務諸表
Annual | 2022 |
収益: | ¥113.27B |
総利益: | ¥50.17B (44.29 %) |
EPS: | ¥82.42 |
FY | 2022 |
収益: | ¥113.27B |
総利益: | ¥50.17B (44.29 %) |
EPS: | ¥82.42 |
FY | 2022 |
収益: | ¥105.53B |
総利益: | ¥49.44B (46.85 %) |
EPS: | ¥68.62 |
FY | 2021 |
収益: | ¥102.90B |
総利益: | ¥51.63B (50.17 %) |
EPS: | ¥106.99 |
Financial Reports:
No articles found.
KYORIN Holdings, Inc. Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
¥20.00 (N/A) |
¥0 (N/A) |
¥32.00 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | ¥10.00 | 2006-09-26 |
Last Dividend | ¥32.00 | 2023-03-30 |
Next Dividend | ¥0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 35 | -- |
Total Paid Out | ¥862.50 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.6 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 4.34 | |
Div. Directional Score | 7.48 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
8125.T | Ex Dividend Knight | 2024-02-28 | Annually | 0 | 0.00% | |
7463.T | Ex Dividend Junior | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
6678.T | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% | |
6023.T | Ex Dividend Knight | 2024-03-28 | Annually | 0 | 0.00% | |
4716.T | Ex Dividend Junior | 2023-05-30 | Annually | 0 | 0.00% | |
3946.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
3168.T | Ex Dividend Junior | 2023-08-30 | Semi-Annually | 0 | 0.00% | |
2150.T | Ex Dividend Knight | 2023-12-29 | Annually | 0 | 0.00% | |
9663.T | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% | |
8624.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0356 | 1.500 | 9.29 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0238 | 1.200 | 9.21 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0339 | 1.500 | -0.735 | -1.102 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 2.53 | 0.800 | 2.34 | 1.871 | [1 - 3] |
quickRatioTTM | 1.327 | 0.800 | 6.90 | 5.52 | [0.8 - 2.5] |
cashRatioTTM | 0.402 | 1.500 | 8.88 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.116 | -1.500 | 8.06 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 75.14 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 146.46 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 146.46 | 2.00 | 10.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.164 | -1.500 | 9.34 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.429 | 1.000 | 6.18 | 6.18 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0408 | 1.000 | -1.185 | -1.185 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.405 | 1.000 | 8.86 | 8.86 | [0.2 - 2] |
assetTurnoverTTM | 0.670 | 0.800 | 8.87 | 7.10 | [0.5 - 2] |
Total Score | 10.62 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 24.65 | 1.000 | 7.61 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0339 | 2.50 | -0.472 | -1.102 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 146.46 | 2.00 | 10.00 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 2.84 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 146.46 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 1.226 | 1.500 | 5.16 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0702 | 1.000 | -0.745 | 0 | [0.1 - 0.5] |
Total Score | 4.34 |
KYORIN Holdings, Inc.
KYORIN Holdings, Inc., through its subsidiaries, researches and develops, produces, and sells ethical and generic drugs in Japan and internationally. The company offers Flutiform, a drug for the treatment of asthma; Desalex, an antiallergic agent; Beova, Uritos, and Imidafenacin KYORIN therapeutic agents for overactive bladder; Lasvic, a quinolone synthetic antibacterial agent; Pentasa, a remedy for ulcerative colitis/Crohn's disease; Nasonex, an allergic rhinitis therapeutic agent; and Kipres, a leukotriene receptor antagonist anti-bronchial asthma and allergic rhinitis drug. It also provides Mucodyne, a mucoregulating drug; Montelukast KM, a drug for the treatment of bronchial asthma and allergic rhinitis; GeneSoC, a real-time PCR system; Rubysta, a disinfectant cleaner; Milton, a disinfectant; over-the-counter drugs; prescription medicines and quasi-drugs, diagnostics, and industrial chemicals; and reagents and intermediates. In addition, the company offers subcontracted drug manufacturing services. Further, it is involved in the discovery and evaluation of candidate compounds; and research and analysis of other companies' technologies and collection of information concerning clinical trial. KYORIN Holdings, Inc. was founded in 1923 and is based in Tokyo, Japan.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。